SynthesisFrontiers in oncology2025
Cancer outcomes of pregnancy after diagnosis of breast cancer in premenopausal women: an updated systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer is a type of hormone-driven cancer, and pregnancy may increase the risk of recurrence in patients due to hormone surge. Our study was designed to explore the cancer outcomes of premenopausal women who had primary breast cancer and who became pregnant at any time after diagnosis. Methods: Searches were conducted in ten databases until July 2024, with no language restrictions. We analyzed aggregate data across all study populations and performed subgroup analyses by stage, estrogen receptor status, BRCA mutation status, HER2 status, previous treatment, lymph node status, interval between pregnancy and diagnosis, pregnancy type, reproductive status, and breastfeeding status. Results: Fifty-two studies were included. The pregnancy group had longer overall survival (n = 18) [RR = 1.09 (1.06, 1.12), P < 0.001]. Nine studies reported the same results [HR = 0.60 (0.48, 0.73), P < 0.001]. The disease-free survival (n = 7) of the pregnancy group was not significantly longer [HR = 0.90 (0.79, 1.02), P = 0.111]. The pregnancy group had longer breast cancer-specific survival (n = 3) [HR = 0.55 (0.40, 0.76), P < 0.001]. The pregnancy group had a lower recurrence rate (n = 17) [RR = 0.61 (0.55, 0.68), P < 0.001]. The pregnancy group had a higher loco-regional recurrence rate, although the difference was not statistically significant (n = 4) [RR = 1.04 (0.74, 1.47), P = 0.814]. The pregnancy group had a lower distant recurrence rate (n = 5) [RR = 0.50 (0.37, 0.68), P < 0.001]. The pregnancy group had a higher contralateral breast cancer rate, although the difference was not statistically significant (n = 3) [RR = 1.06 (0.76, 1.48), P = 0.742]. Discussion: Our findings indicate that pregnancy after breast cancer does not lead to adverse cancer outcomes. Stage, estrogen receptor status, therapy choice (hormone, chemotherapy, or endocrine therapy combined with chemotherapy), and reproductive status are not associated with overall survival. BRCA2 mutation may negatively affect disease-free survival in pregnant patients with breast cancer. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024499971.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.